Literature DB >> 20964730

Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease.

Begoña Villar-Cheda1, Jannette Rodríguez-Pallares, Rita Valenzuela, Ana Muñoz, Maria J Guerra, Ovidiu C Baltatu, Jose L Labandeira-Garcia.   

Abstract

The basal ganglia have a local renin-angiotensin system and it has been shown that the loss of dopaminergic neurons induced by neurotoxins is amplified by local angiotensin II (AII) via angiotensin type 1 receptors (AT1) and nicotinamide adenine dinucleotide phosphate (NADPH) complex activation. Recent studies have revealed a high degree of counter-regulatory interactions between dopamine and AII receptors in non-neural cells such as renal proximal tubule cells. However, it is not known if this occurs in the basal ganglia. In the striatum and nigra, depletion of dopamine with reserpine induced a significant increase in the expression of AT1, angiotensin type 2 receptors (AT2) and the NADPH subunit p47(phox) , which decreased as dopamine function was restored. Similarly, 6-hydroxydopamine-induced chronic dopaminergic denervation induced a significant increase in expression of AT1, AT2 and p47(phox) , which decreased with L-dopa administration. A significant reduction in expression of AT1 mRNA was also observed after administration of dopamine to cultures of microglial cells. Transgenic rats with very low levels of brain AII showed increased AT1, decreased p47 (phox) and no changes in AT2 expression, whereas mice deficient in AT1 exhibited a decrease in the expression of p47 (phox) and AT2. The administration of relatively high doses of AII (100 nm) decreased the expression of AT1, and the increased expression of AT2 and p47(phox) in primary mesencephalic cultures. The results reveal an important interaction between the dopaminergic and local renin-angiotensin system in the basal ganglia, which may be a major factor in the progression of Parkinson's disease.
© 2010 The Authors. European Journal of Neuroscience © 2010 Federation of European Neuroscience Societies and Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20964730     DOI: 10.1111/j.1460-9568.2010.07448.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  29 in total

1.  Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson's Disease Models.

Authors:  Pablo Garrido-Gil; Ana I Rodriguez-Perez; Antonio Dominguez-Meijide; Maria J Guerra; Jose L Labandeira-Garcia
Journal:  Mol Neurobiol       Date:  2018-02-05       Impact factor: 5.590

2.  Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease.

Authors:  Jannette Rodriguez-Pallares; Juan Andres Parga; Belen Joglar; Maria Jose Guerra; Jose Luis Labandeira-Garcia
Journal:  Age (Dordr)       Date:  2011-06-29

3.  Laser capture microdissection protocol for gene expression analysis in the brain.

Authors:  P Garrido-Gil; P Fernandez-Rodríguez; J Rodríguez-Pallares; Jose L Labandeira-Garcia
Journal:  Histochem Cell Biol       Date:  2017-05-31       Impact factor: 4.304

4.  Aging, Angiotensin system and dopaminergic degeneration in the substantia nigra.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Begoña Villar-Cheda; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Maria J Guerra
Journal:  Aging Dis       Date:  2011-04-20       Impact factor: 6.745

5.  Angiotensin-II mediates nonmuscle myosin II activation and expression and contributes to human keloid disease progression.

Authors:  Jennifer E Bond; Andrew Bergeron; Peter Thurlow; M Angelica Selim; Edith V Bowers; Anna Kuang; Howard Levinson
Journal:  Mol Med       Date:  2011-07-21       Impact factor: 6.354

Review 6.  Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates.

Authors:  Timothy J Collier; Nicholas M Kanaan; Jeffrey H Kordower
Journal:  Nat Rev Neurosci       Date:  2011-05-18       Impact factor: 34.870

7.  Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Begoña Villar-Cheda; Rita Valenzuela; Maria J Guerra
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

8.  Brain Angiotensin II AT1 receptors are involved in the acute and long-term amphetamine-induced neurocognitive alterations.

Authors:  Natalia Andrea Marchese; Emilce Artur de laVillarmois; Osvaldo Martin Basmadjian; Mariela Fernanda Perez; Gustavo Baiardi; Claudia Bregonzio
Journal:  Psychopharmacology (Berl)       Date:  2015-11-28       Impact factor: 4.530

9.  Identification of key pathways and transcription factors related to Parkinson disease in genome wide.

Authors:  Bin Zhang; Cuiping Xia; Qunfeng Lin; Jie Huang
Journal:  Mol Biol Rep       Date:  2012-10-18       Impact factor: 2.316

Review 10.  The Renin-Angiotensin System Modulates Dopaminergic Neurotransmission: A New Player on the Scene.

Authors:  Tamara Kobiec; Matilde Otero-Losada; Guenson Chevalier; Lucas Udovin; Sofía Bordet; Camila Menéndez-Maissonave; Francisco Capani; Santiago Pérez-Lloret
Journal:  Front Synaptic Neurosci       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.